High aldehyde dehydrogenase activity at diagnosis predicts relapse in patients with t(8;21) acute myeloid leukemia

Cancer Medicine
Lu YangYa-Zhen Qin

Abstract

Acute myeloid leukemia (AML) with t(8;21) is a heterogeneous disease. Although the detection of minimal residual disease (MRD), which is indicated by RUNX1-RUNX1T1 transcript levels, plays a key role in directing treatment, risk stratification needs to be improved, and other markers need to be assessed. A total of 66 t(8;21) AML patients were tested for aldehyde dehydrogenase (ALDH) activity by flow cytometry at diagnosis, and 52 patients were followed up for a median of 20 (1-34) months. The median percentage of CD34+ALDH+, CD34+CD38-ALDH+, and CD34+CD38+ALDH+ cells among nucleated cells were 0.028%, 0.012%, and 0.0070%, respectively. The CD34+ALDH+-H, CD34+CD38-ALDH+-H, and CD34+CD38+ALDH+-H statuses (the percentage of cells that were higher than the individual cutoffs) were all significantly associated with a lower 2-year relapse-free survival (RFS) rate in both the whole cohort and adult patients (P = .015, .016, and .049; P = .014, .018, and .032). Patients with < 3-log reduction in the RUNX1-RUNX1T1 transcript level after the second consolidation therapy (defined as MRD-H) had a significantly lower 2-year RFS rate than patients with ≥ 3-log reduction (MRD-L) (P = .017). The CD34+ALDH+ status at diagnosis was then combined...Continue Reading

References

Aug 4, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R F SchlenkG Heil
Aug 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guido MarcucciClara D Bloomfield
Sep 17, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Anna van RhenenGerrit Jan Schuurhuis
Aug 22, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter PaschkaUNKNOWN Cancer and Leukemia Group B
Aug 31, 2006·British Journal of Haematology·Frederick R AppelbaumElihu H Estey
Oct 5, 2010·Molecular Cancer Therapeutics·Charles N LandenAnil K Sood
Aug 30, 2011·Nature Medicine·Kolja EppertJohn E Dick
Dec 30, 2014·International Journal of Cancer. Journal International Du Cancer·Van T HoangChristoph Lutz
May 18, 2018·Neoplasia : an International Journal for Oncology Research·Katharina BlattPeter Valent

❮ Previous
Next ❯

Methods Mentioned

BETA
FACS
PCR
flow cytometry

Software Mentioned

SPSS
GraphPad Prism
Kaluza flow

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukaemia & RNA

Acute myeloid leukaemia (AML) is a common hematological type of cancer. As the population ages, there has been a rise in the frequency of AML. RNA expression has been used to see if there are different genetic profiles that exist within AML and whether these may underpin the variations in survival rates. Here is the latest research on AML and RNA.